NONMEM Users Network Archive

Hosted by Cognigen

Open position as Director, Quantitative Clinical Pharmacology at GSK

From: Stefano Zamuner <stefano.6.zamuner>
Date: Thu, 24 May 2018 14:58:29 +0000

Dear all,

The department of Clinical Pharmacology Modelling and Simulation (CPMS) at =
GlaxoSmithKline is recruiting a Quantitative Clinical Pharmacologist at the=
 Director level. CPMS is a science driven group delivering clinical pharmac=
ology and modelling & simulation excellence to development programs. A succ=
essful candidate will have the opportunity to work on both small molecules =
and biologics in the immuno-inflammation area although there may be opportu=
nities in the future to contribute to programs in other therapy areas. Posi=
tion can be based at GSK UK or US sites, with a preference for the Stevenag=
e, UK site.

Best Regards

Stefano Zamuner PhD
Senior Director Clinical Pharmacology
Head Immuno-Inflammation Clinical Pharmacology Modeling and Simulation
RD Projects Clinical Platforms & Sciences
GSK Senior Fellow

Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1=
 2NY, UK
Email stefano.6.zamuner
Tel +44 1438 766950<> | Twitter<> | YouTub=
e<> | Facebook<http://www.facebook.c=
om/glaxosmithkline> | Flickr<


GSK monitors email communications sent to and from GSK in order to protect =
GSK, our employees, customers, suppliers and business partners, from cyber =
threats and loss of GSK Information. GSK monitoring is conducted with appro=
priate confidentiality controls and in accordance with local laws and after=
 appropriate consultation.


This e-mail was sent by GlaxoSmithKline Services Unlimited
(registered in England and Wales No. 1047315), which is a
member of the GlaxoSmithKline group of companies. The
registered address of GlaxoSmithKline Services Unlimited
is 980 Great West Road, Brentford, Middlesex TW8 9GS.

(image/png attachment: image003.png)

Received on Thu May 24 2018 - 10:58:29 EDT

The NONMEM Users Network is maintained by ICON plc. Requests to subscribe to the network should be sent to:

Once subscribed, you may contribute to the discussion by emailing: